Dermatology Research and Practice / 2014 / Article / Tab 1 / Review Article
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management Table 1 Summery of oral antibiotic in the prevention of EGFRI-induced skin toxicity.
Author Year EGFRI agent Patients (
) Antibiotic Objective Results Quality of life Scope et al. 2007 [35 ] Cetuximab 48 Minocycline To decrease or prevent skin toxicity Lower facial lesion count with minocycline (
value 0.05) Lower itch severity Jatoi et al. 2008 [36 ] Multiple 61 Tetracycline To prevent or decrease grade ≥2 rash No difference in rash incidence (70% versus 76%
value 0.61) Significant lower grade ≥2 rash (17% versus 55%,
value 0.04) Less burning and irritation with tetracycline Laouture et al. 2010 [37 ] Panitumumab 95 Doxycycline (plus skin moisturizer, sunscreen, and topical steroid) as prophylactic regimen To decrease grade ≥2 toxicity Lower incidence of grade ≥2 toxicity in prophylactic regimen (29 versus 62%, OR, 0.3; 95% CL, 0.1 to 0.6) More improvement of DLQI in prophylactic group Deplaque et al. 2010 [38 ]. Erlotinib 147 Doxycycline To prevent or decrease severity of folliculitis No difference in folliculitis incidence (68% versus 82%,
value = 0.055). Significant decrease in severity
Lower incidence of grade ≥2 folliculitis in doxycycline arm (39% versus 82%) NA
All are RCTs. DLQI: Dermatologic Life Quality Index. NA: not assessed.